Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Claire N. Thant"'
Autor:
Hideaki Bando, Emily E. Van Seventer, Takayuki Yoshino, Ryan B. Corcoran, Aparna Raj Parikh, Hiroya Taniguchi, Neal Rosen, Elisa de Stanchina, Sebastian Mondaca, Hiromichi Ebi, Daisuke Kotani, Huiyong Zhao, Rona Yaeger, Zhan Yao, Claire N. Thant
Publikováno v:
Clin Cancer Res
Purpose: While mutations in BRAF in metastatic colorectal cancer (mCRC) most commonly occur at the V600 amino acid, with the advent of next-generation sequencing, non-V600 BRAF mutations are increasingly identified in clinical practice. It is unclear
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::83bd74f6eb04f8555c45047727ea594e
https://doi.org/10.1158/1078-0432.ccr-19-2004
https://doi.org/10.1158/1078-0432.ccr-19-2004
Autor:
Timothy J. Hansen, Bhasirie Thuamsang, Joseph A. White, Rupkatha Banerjee, Claire N. Thant, Shermali Gunawardena
Publikováno v:
Apoptosis. 24:341-358
High levels of oxidative stress is detected in neurons affected by many neurodegenerative diseases, including Huntington’s disease (HD). Many of these diseases also show neuronal cell death and axonal transport defects. While nuclear inclusions/acc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a8f836c63a17768ab7c26003ec008d0
https://doi.org/10.1007/s10495-019-01520-4
https://doi.org/10.1007/s10495-019-01520-4
Autor:
Hayley Hoffmar-Glennon, Layne Thurston, Joseph A. White, Shermali Gunawardena, Claire N. Thant, Katherine Zimmerman, Julia Vail, Saad Navid Rahman, Thomas J. Krzystek, Gary J. Iacobucci
Publikováno v:
Acta Neuropathologica Communications
Acta Neuropathologica Communications, Vol 8, Iss 1, Pp 1-22 (2020)
Acta Neuropathologica Communications, Vol 8, Iss 1, Pp 1-22 (2020)
Huntington’s disease (HD) is characterized by protein inclusions and loss of striatal neurons which result from expanded CAG repeats in the poly-glutamine (polyQ) region of the huntingtin (HTT) gene. Both polyQ expansion and loss of HTT have been s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5543fa2876d0619b98d51ffde27b1aec
https://doi.org/10.1186/s40478-020-00964-z
https://doi.org/10.1186/s40478-020-00964-z
Autor:
Xinwen Zhang, Min Wei, Badreddin Edris, Xi Yuan, Mary Lou Smith, Lai Wang, Rong Du, Changyou Zhou, Neal Rosen, Zhan Yao, Claire N. Thant, Lusong Luo, Todd Shearer, Shing-Hu Cheung
Publikováno v:
Cancer Research. 80:6415-6415
K-RAS mutation represents one of the most frequent genetic alterations in cancers. Monotherapy approaches targeting RAS downstream effectors such as MEK and ERK have had limited clinical success in patients with K-RAS-mutated cancers. The reduced sen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::32bad8b34499531246ce879a8d6c6d41
https://doi.org/10.1158/1538-7445.am2020-6415
https://doi.org/10.1158/1538-7445.am2020-6415